• In the past week, Amgen reported first-quarter 2026 results showing revenue of US$8,618 million and net income of US$1,819 million, with both basic and diluted earnings per share from continuing operations rising year on year, and confirmed it has completed a long-running share repurchase program totaling about US$60.59 billion.
• Management also raised full-year 2026 revenue guidance and highlighted strong volume growth across key drugs and advancing late-stage candidates, while announcing senior leadership changes that further emphasize artificial intelligence and data as core to Amgen’s future operations.
• We’ll now examine how Amgen’s raised 2026 revenue guidance and volume-led growth affect its existing investment narrative and risk-reward balance.

Find 50 companies with promising cash flow potential yet trading below their fair value.

Amgen Investment Narrative Recap

To own Amgen today, you need to believe its volume-led growth and late-stage pipeline can more than offset pricing pressure and biosimilar competition. The key short term catalyst is execution on fast-growing products and obesity and oncology trials, while the biggest current risk is erosion in aging franchises and any fallout from regulatory scrutiny such as the FDA’s proposed Tavneos withdrawal. The Q1 beat and higher 2026 revenue guidance support the catalyst but do not remove these risks.

The most relevant recent announcement here is Amgen’s raised 2026 revenue outlook to US$37.1 billion to US$38.5 billion, backed by 9% volume growth and 16 brands with double digit sales increases. This guidance increase links directly to the core catalyst of newer products ramping fast enough to cushion patent expirations and biosimilar pressure, and it sets a higher bar for execution just as leadership is reorienting around AI and data across R&D and global markets.

Yet even with stronger near term guidance, investors should be aware of the mounting biosimilar and pricing pressures that could...

Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028.

Uncover how Amgen's forecasts yield a $350.03 fair value, a 6% upside to its current price.

Exploring Other Perspectives

While consensus sees steady progress, the most pessimistic analysts were assuming roughly flat revenue of about US$36.7 billion and only US$7.6 billion of earnings by 2029, so you should recognize that views on Amgen’s risks and opportunities can differ widely and that both sets of expectations may shift after this latest guidance and volume performance.

Explore 4 other fair value estimates on Amgen - why the stock might be worth just $350.03!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amgen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.